Alpha 2.0
Login Register
» Articles » PMID: 1974499

Hemodynamic Differences Between Carvedilol and Labetalol in the Cutaneous Circulation

Overview
Journal Eur J Clin Pharmacol
Specialty Pharmacology
Date 1990 Jan 11
PMID 1974499
Citations 8
Authors
R R Ruffolo Jr
C F Sauermelch
R N Willette
Affiliations
Soon will be listed here.
Abstract

The effects of labetalol and carvedilol on local cutaneous microvascular perfusion and calculated local cutaneous microvascular resistance were investigated in anesthetized rats at submaximal doses that produced equivalent reductions in blood pressure and heart rate. Labetalol decreased cutaneous perfusion (-25% +/- 3%) without significantly affecting cutaneous vascular resistance (-6% +/- 3%). In marked contrast, carvedilol dramatically increased cutaneous perfusion (+64% +/- 9%) and significantly reduced cutaneous vascular resistance (-57% +/- 3%). These results suggest that carvedilol and labetalol possess differences in the mechanisms by which they produce vasodilation in vivo.

Citing Articles

Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Dunn C, Lea A, Wagstaff A Drugs. 1997; 54(1):161-85.

PMID: 9211087 DOI: 10.2165/00003495-199754010-00015.

A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders.

Louis W, Krum H, Conway E Drug Saf. 1994; 11(2):86-93.

PMID: 7946002 DOI: 10.2165/00002018-199411020-00003.

Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Morgan T Clin Pharmacokinet. 1994; 26(5):335-46.

PMID: 7914479 DOI: 10.2165/00003088-199426050-00002.

Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

McTavish D, Sorkin E Drugs. 1993; 45(2):232-58.

PMID: 7681374 DOI: 10.2165/00003495-199345020-00006.

Long-term hemodynamic effects of antihypertensive treatment.

Lund-Johansen P, Omvik P, Nordrehaug J Clin Investig. 1992; 70 Suppl 1:S58-64.

PMID: 1350486 DOI: 10.1007/BF00207613.

References
1.
Hattori Y, Nakaya H, Endou M, Nakao Y, Kanno M . Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. J Cardiovasc Pharmacol. 1989; 13(4):572-9. View
2.
Nichols A, Sulpizio A, Ashton D, Hieble J, Ruffolo Jr R . In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 1989; 39(5):327-36. DOI: 10.1159/000138616. View
3.
Rahn K . Antihypertensive compounds with combined actions. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S18-22. View
4.
Sponer G, Strein K, Bartsch W . Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S42-8. View
5.
Sponer G, Bartsch W, Strein K, Bohm E . Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987; 9(3):317-27. DOI: 10.1097/00005344-198703000-00009. View